LOGIN  |  REGISTER
C4 Therapeutics
Amneal Pharmaceuticals

Kovo HealthTech Announces Signing of Forbearance Agreement with Its Primary Lender

April 03, 2024 | Last Trade: C$0.06 0.00 0.00

Vancouver, British Columbia--(Newsfile Corp. - April 3, 2024) - Kovo HealthTech Corporation (TSXV: KOVO) (the "Company" or "Kovo") - a leader in healthcare Billing-as-a-Service - announces a forbearance agreement with its primary lender Avonlea Ventures #2 Inc. ("AVI"), a corporation wholly-owned by Micheal Steele, a director of Kovo.

Kovo's primary lender, AVI entered into a forbearance agreement (the "Forbearance Agreement") dated February 27th, 2024 in connection with the investment agreement and senior loan and security agreement (the "Credit Agreement") entered into between AVI and Kovo dated April 20, 2023 (see press release dated April 21, 2023). Pursuant to the Forbearance Agreement, AVI advanced an additional US$1,250,000 under the Credit Agreement and, notwithstanding the April 30, 2024 maturity date of the indebtedness advanced under the Credit Agreement, AVI has agreed to forbear on taking certain enforcement actions under the Credit Agreement until April 20, 2024 so long management delivers an operating plan acceptable to the lender in its sole and unfettered discretion (the "New Operating Plan"). In the event that such condition is satisfied, the forbearance period will extend until June 30, 2024. The forbearance is subject to a fee equal to 20% of the total indebtedness as at February 27, 2024 and to certain additional conditions customary for transactions of this nature such as strict adherence to the Credit Agreement and the approval by the independent directors of the New Operating Plan. The forbearance will allow Kovo to continue operating while AVI assesses the business strengths and opportunities. AVI's willingness to enter into the Forbearance Agreement and work collaboratively with the Board of Directors in the preparation of the New Operating Plan indicates a positive outlook on the Kovo business and its re-focused business model. AVI has assigned Mr. Justin Anderson as Chief Restructuring Officer to assist management to immediately begin the process of implementing changes to grow revenues, structure the business more efficiently and prepare the baseline business for transacting within its marketplace. Although Kovo has drawn approximately USD$5.0 million of the available USD$7.0 million under the Credit Agreement, AVI has indicated it may permit Kovo to draw on the remaining USD$2.0 million under certain circumstances should it be satisfied that certain operating conditions can be met.

About Kovo HealthTech Corporation

Kovo HealthTech Corporation is a growing healthcare technology company that specializes in Billing-as-a-Service offering SaaS-style recurring revenue contracts and software for more than 1700 US healthcare providers. Kovo helps healthcare providers digitally track and manage complex patient care registration, services, billing and payments in a seamless way, using its industry-leading OneRev technology platform. Currently, through its clients, Kovo processes over $250 million CAD ($200M USD) in annual billing transactions for more than 4.5 million patients. By offering effective billing practices and technology through long-term SaaS-style contracts, Kovo helps healthcare practitioners get paid so they can focus on offering quality care. To learn more about Kovo and to keep up-to-date on Kovo news, visit www.kovo.co.

For more information:
Greg Noble, CEO
This email address is being protected from spambots. You need JavaScript enabled to view it.
1-866-558-6777

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release

Terns Pharmaceuticals

Stock Quote

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB